FindTrial
Sign In

Clinical comprehensive evaluation of thrombopoietin receptor agonists in the treatment of primary immune thrombocytopenia

Clinical comprehensive evaluation of thrombopoietin receptor agonists in the treatment of primary immune thrombocytopenia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097299
Enrollment
Unknown
Registered
2025-02-17
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary immune thrombocytopenia

Interventions

Herombopag group:None
Other TPO-RA group:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. >= 18 years old; 2. Diagnosed with ITP; 3. At least one previous ITP medication (including steroids) or splenectomy treatment was ineffective (PLT<30x109/L) or recurred; 4. Patients who are able to collect complete information related to the purpose of this study;

Exclusion criteria

Exclusion criteria: 1.None;

Design outcomes

Primary

MeasureTime frame
Platelet counts;Proportion of patients who achieved a complete response after 8 weeks of treatment;—

Secondary

MeasureTime frame
The proportion of patients with early response and initial response was achieved;—

Countries

China

Contacts

Public ContactYu Zhang

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

whxhzy@163.com+86 27 85726685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026